DOI: 10.6077/f5pk-hs90
title: Data from Two-year Randomized Controlled Study on Daily Self-weighing Among Workplace Employees in Ithaca, NY, 2017-2019

description: &lt;p&gt;To examine the efficacy of daily self-weighing to prevent age-related weight gain among university employees, in this two-year randomized controlled trial among 286 employees of a single university, participants were randomized to receive a blue-tooth enabled scale and daily self-weigh (intervention group) or a no-contact control group. Participants in the intervention received automated reminder emails if they did not weigh consecutively for three or more days. Height and weight were measured for all participants at baseline and two-year follow-up. The primary outcome was weight change over the two years.&lt;/p&gt;
&lt;p&gt;This dataset includes the survey data and weight measurements of the participants at both the enrollment and end-of-study sessions.&lt;/p&gt;
description: version_history: Version 2 - changed data files from restricted to open based on email from Yingyi Zhong. 30 APR 2021 

Version 1 restriction notes - Data available upon request. If the data is requested, the authors can give permission for the individuals to access the data. Please contact Yingyi Zhong at yz435(at)cornell.edu or the authors for authorization. Version 1 Internal notes; Requirement for author permission expires on 4 JAN 2041 and can be opened to public access per email from data depositor on 4 JAN 2021. -jb; 
collection_notes: Additional contributors: Yingyi Zhong, Cornell University, ORCID ID: 0000-0002-6941-4821

Additional keywords: Daily self-weighing, age-related weight gain, weight gain prevention, preventative medicine.

The Weigh2Go study was a two-year, prospective, randomized control trial of daily self-weighing, conducted at Cornell University. The purpose of our randomized controlled trial was to examine the efficacy of daily self-weighing alone to prevent age-related weight gain among university employees. The primary outcome was change in body weight over two years from summer 2017 to summer 2019. Eligible participants that met the inclusion and exclusion criteria consented to participate, completed the baseline survey online, and attended an enrollment session. At the enrollment session, participants’ heights (cm) and weights (kg) were measured with minimal clothing (paper gown and undergarment) by trained research assistants and they were randomized to either the intervention or control group using a random number generated by Excel. Two years after baseline, both intervention and control group participants completed an online end-of-study survey and returned to the research unit to have their weight and height measured by trained research assistants. The sample size was calculated based on an 80% statistical power to detect a 1-kg difference in weight change between the daily self-weighing intervention and control groups, indicating 240 participants (120 participants in each group) are needed. Among the baseline characteristics, continuous variables were summarized as means with standard deviations while categorical variables were summarized as percentages. Large variation in the weighing frequency over two years was observed among the intervention group participants, indicating an incomplete adherence to the study protocol and thus limiting the ability of intent-to-treat analysis to estimate the efficacy of daily self-weighing intervention. To obtain a more accurate measurement of the efficacy of daily self-weighing. a per-protocol analysis was conducted post-hoc. In the per-protocol analysis, only the participants that completed the study and adhered to their assigned arm were included. We defined daily self-weighing as weighing at least 70% of the days (5 days/week) or more according to a similar two-year daily self-weighing study conducted by Crane et al. Adherence for the control group was defined as weighing less than daily.

All protocols and procedures were approved by the Institutional Review Broad for Human Subjects Research of the university in 2016, and the trial was registered on ClinicalTrails.gov (NCT03717428)